---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-277569"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:49:29.954407+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Kyverna Therapeutics reports Q3 results, positive gMG interim data, $150M loan facility, SPS data early 2026

## Summary
- Kyverna reported Q3 2025 net loss of $36.8M ($0.85 per share), R&D expenses $30.5M, G&A $8.3M; cash $171.1M as of Sep 30, 2025.
- Positive interim Phase 2 data in generalized myasthenia gravis: all primary and secondary endpoints met, 100% of patients achieved sustained reductions in MG-ADL and QMG at 24 weeks.
- Topline data from registrational stiff person syndrome trial expected early 2026 (narrowed from 1H 2026); BLA submission anticipated in 1H 2026.
- Closed up to $150M loan facility with Oxford Finance, initial $25M drawn; cash runway extended into 2027.
- On track to file IND for KYV-102 (whole blood rapid manufacturing) in Q4 2025; Phase 3 gMG enrollment by year-end.

## SEC filing metadata
- accession: 0001193125-25-277569
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000119312525277569/0001193125-25-277569-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000119312525277569/kytx-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-277569
- JSON: https://secwatch.observer/filing/0001193125-25-277569.json
- Plain text: https://secwatch.observer/filing/0001193125-25-277569.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.